Bibliography
- Ding C, Foote S, Jones G. B-cell-targeted therapy for systemic lupus erythematosus: an update. BioDrugs 2008;22(4):239-49
- Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 2006;5(7):564-76
- Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Ann Rev Immunol 2006;24:467-96
- Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 2006;66(15):1933-48
- Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48(6):1484-92
- Cancro MP. The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation. Immunol Rev 2004;202:237-49
- Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285(5425):260-3
- Ding C, Jones G. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr Opin Investig Drugs 2006;7(5):464-72
- Craxton A, Magaletti D, Ryan EJ, Clark EA. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 2003;101(11):4464-71
- Lavie F, Miceli-Richard C, Quillard J, et al. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol 2004;202(4):496-502
- Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Ann Rev Immunol 2003;21:231-64
- Ohata J, Zvaifler NJ, Nishio M, et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005;174(2):864-70
- Scapini P, Nardelli B, Nadali G, et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003;197(3):297-302
- Huard B, Schneider P, Mauri D, et al. T cell costimulation by the TNF ligand BAFF. J Immunol 2001;167(11):6225-31
- Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell disorders. Semin Immunol 2006;18(5):305-17
- Thompson JS, Bixler SA, Qian F, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001;293(5537):2108-11
- Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404(6781):995-9
- Hahne M, Kataoka T, Schroter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998;188(6):1185-90
- Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002;109(1):59-68
- Khare SD, Sarosi I, Xia XZ, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000;97(7):3370-5
- Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003;48(12):3475-86
- Tan SM, Xu D, Roschke V, et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003;48(4):982-92
- Collins CE, Gavin AL, Migone TS, et al. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006;8(1):R6
- Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62(2):168-71
- Seyler TM, Park YW, Takemura S, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005;115(11):3083-92
- Winthrop KL. Serious infections with antirheumatic therapy: are biologicals worse? Ann Rheum Dis 2006;65(Suppl 3):iii54-7
- Moller B, Villiger PM. Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases. Springer Semin Immunopathol 2006;27(4):391-408
- Ding C, Jones G. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Rev Recent Clin Trials 2006;1(3):193-200
- Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-α antagonists. Medicine (Baltimore) 2005;84(5):291-302
- Mugnier B, Balandraud N, Darque A, et al. Polymorphism at position -308 of the tumor necrosis factor α gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003;48(7):1849-52
- Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48(11):3253-65
- Halpern WG, Lappin P, Zanardi T, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 2006;91(2):586-99
- Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10(5):R109
- Genovese M, Filipowicz-Sosnowska A, Merrill J, et al. Differential responsiveness to belimumab (BmAb) in combination with standard of care therapy in RF+, TNF α-inhibitor and methotrexate partial responder subgroups of subjects with moderate-severe rheumatoid arthritis. Arthritis Rheum 2005;52(9):S738
- McKay J, Chwalinska-Sadowska H, Boling E, et al. Belimumab (BmAb), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogenous subject population. Arthritis Rheum 2005;52(9):S710-1
- Stohl W, Chatham W, Weisman M, et al. Belimumab (BmAb), a novel fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), selectively modulates B-cell sub-populations and immunoglobulins in a heterogeneous rheumatoid arthritis subject population. Arthritis Rheum 2005;52(9):S444
- Furie R, Lisse J, Merrill JT, et al. Belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [BLyS]) improves or stabilizes SLE activity in a multicenter phase 2 trial. Arthritis Rheum 2006;54(9):S258
- Strand V, Crawford B, Petri M, et al. Patients with active systemic lupus erythematosus (SLE) treated with belimumab improve health-related quality of life (HRQOL) in a randomized controlled trial (RCT). Arthritis Rheum 2006;54(Suppl):S277-8
- Wallace DJ, Lisse J, Stohl W, et al. Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks. Arthritis Rheum 2006;54(Suppl):S790
- Petri M, Furie R, Ginzler E, et al. Novel combined response endpoint and systemic lupus erythematosus (SLE) flare index (SFI) demonstrate belimumab (fully human monoclonal antibody to BLyS) improves or stabilizes SLE disease activity and reduces flare rate over 2.5 years of therapy. Arthritis Rheum 2007;56(Suppl):1316
- Chatham W, Aranow C, Furie R, et al. Progressive normalization of autoantibody, immunoglobulin, and complement levels over 3 years of belimumab (fully human monoclonal antibody to BlyS) therapy in systemic lupus erythematosus (SLE) patients. Ann Rheum Dis 2008;67(Suppl II):217
- Furie R, Petri M, Weisman MH, et al. Belimumab (fully human monoclonal antibody to BlyS) improved or stabilized systemic lupus erythematosus (SLE) disease activity and reduced flare during 3 years of therapy. Ann Rheum Dis 2008;67(Suppl II):53
- Stohl W, Chatham W, McKay J, et al. progressive normalization of autoantibody, immunoglobulin, and complement levels over 2.5 years of belimumab (fully human monoclonal antibody to BLyS) therapy in systemic lupus erythematosus (SLE) patients. Arthritis Rheum 2007;56(Suppl):426
- Stohl W, Wallace DJ, Merrill JT, et al. Changes in circulating B-cell counts, autoantibody levels and immunoglobulins that associate with therapeutic responsiveness in SLE to BLyS protein antagonism by Belimumab. Arthritis Rheum 2006;54(Suppl):S780
- Ginzler EM, Wallace DJ, Chatham W, et al. Belimumab (fully human monoclonal antibody to BlyS) reduced steroid use in systemic lupus erythematosus (SLE) patients during 3 years of therapy. Ann Rheum Dis 2008;67(Suppl):217
- Merrill JT, Wallace DJ, McKay J, et al. Long-term safety profile of belimumab (fully human monoclonal antibody to BlyS) in patients with systemic lupus erythematosus (SLE). Ann Rheum Dis 2008;67(Suppl):217
- Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350(25):2572-81
- Lavie F, Miceli-Richard C, Ittah M, et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007;66(5):700-3
- Vallerskog T, Heimburger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006;8(6):R167
- Roschke V, Sosnovtseva S, Ward CD, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002;169(8):4314-21
- Dall'era M, Chakravarty E, Genovese M, et al. Trial of Atacicept in patients with systemic lupus erythematosus (SLE). Arthritis Rheum 2006;54(12):4042-3
- Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349(16):1526-33
- Huizinga TW, Boling E, Valente R, et al. Genetic and environmental risk factors, disease outcome and responses to anti B-Cell therapy belimumab indicate Anti-CCP positive RA is a distinct disease entity. Arthritis Rheum 2006;54(9):S368